PTA Peripheral DCB Catheters - Medical Devices Pipeline Assessment, 2020

Summary

The publisher's Medical Devices sector report, “PTA Peripheral DCB Catheters-Medical Devices Pipeline Assessment, 2020“ A PTA Peripheral DCB Catheter is a drug-coated percutaneous transluminal angioplasty (PTA) balloon intended to prevent restenosis, or restenosis of the peripheral arteries.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

Extensive coverage of the PTA Peripheral DCB Catheters under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of PTA Peripheral DCB Catheters and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment/industry

Reasons to Buy

The report enables you to -

Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of PTA Peripheral DCB Catheters under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date

1 Table of Contents

2 Introduction

2.1 PTA Peripheral DCB Catheters Overview

3 Products under Development

3.1 PTA Peripheral DCB Catheters-Pipeline Products by Stage of Development
3.2 PTA Peripheral DCB Catheters-Pipeline Products by Territory
3.3 PTA Peripheral DCB Catheters-Pipeline Products by Regulatory Path
3.4 PTA Peripheral DCB Catheters-Pipeline Products by Estimated Approval Date
3.5 PTA Peripheral DCB Catheters-Ongoing Clinical Trials

4 PTA Peripheral DCB Catheters-Pipeline Products under Development by Companies

4.1 PTA Peripheral DCB Catheters Companies-Pipeline Products by Stage of Development
4.2 PTA Peripheral DCB Catheters-Pipeline Products by Stage of Development

5 PTA Peripheral DCB Catheters Companies and Product Overview

5.1 AnGes Inc Company Overview
5.2 AngioCure, Inc. Company Overview
5.3 Boston Scientific Corp Company Overview
5.4 Concept Medical Inc Company Overview
5.5 Contego Medical LLC Company Overview
5.6 eucatech AG Company Overview
5.7 Genesis MedTech International Pvt Ltd Company Overview
5.8 Lifetech Scientific (Shenzhen) Co Ltd Company Overview
5.9 Lutonix Inc Company Overview
5.10 M.A. Med Alliance SA Company Overview
5.11 Medtronic Plc Company Overview
5.12 Micell Technologies Inc Company Overview
5.13 Orchestra BioMed Inc Company Overview
5.14 Pulsus Medical LLC (Inactive) Company Overview
5.15 QualiMed Innovative Medizinprodukte GmbH Company Overview
5.16 SiL Vascular Ltd Company Overview
5.17 Spectranetics Corp Company Overview
5.18 SurModics Inc Company Overview
5.19 Tailored Medical Devices Inc Company Overview
5.20 TransMed7 LLC Company Overview
5.21 Vascular Nanotransfer Technologies Company Overview

6 PTA Peripheral DCB Catheters-Recent Developments7 Appendix

List of Tables

Table 1: PTA Peripheral DCB Catheters-Pipeline Products by Stage of Development
Table 2: PTA Peripheral DCB Catheters-Pipeline Products by Territory
Table 3: PTA Peripheral DCB Catheters-Pipeline Products by Regulatory Path
Table 4: PTA Peripheral DCB Catheters-Pipeline Products by Estimated Approval Date
Table 5: PTA Peripheral DCB Catheters-Ongoing Clinical Trials
Table 6: PTA Peripheral DCB Catheters Companies-Pipeline Products by Stage of Development
Table 7: PTA Peripheral DCB Catheters-Pipeline Products by Stage of Development
Table 8: AnGes Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: NF-kB Decoy Oligo Coated PTA Balloon Catheter-Product Status
Table 10: NF-kB Decoy Oligo Coated PTA Balloon Catheter-Product Description
Table 11: AngioCure, Inc. Pipeline Products &Ongoing Clinical Trials Overview
Table 12: AngioCure TOP-C Smart Balloon Catheter-Product Status
Table 13: AngioCure TOP-C Smart Balloon Catheter-Product Description
Table 14: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 15: Ranger Drug-Coated Balloon-Product Status
Table 16: Ranger Drug-Coated Balloon-Product Description
Table 17: Boston Scientific Corp-Ongoing Clinical Trials Overview
Table 18: Ranger Drug-Coated Balloon-A Randomized Trial Comparing Drug-coated Balloon and Regular Balloon for Dialysis Access Stent Graft Restenosis
Table 19: Ranger Drug-Coated Balloon-Efficacy of Rotational Atherectomy System Associated with Drug Coated Balloon Angioplasty (with or without Stent Placement) in the Management of Lower Limb Ischemia (ELLIPSE): Real Life Observational Study
Table 20: Ranger Drug-Coated Balloon-JETStream AtheRectomy with Adjunctive Paclitaxel-coated Balloon Angioplasty Versus Balloon Angioplasty Followed by Paclitaxel-coated Balloon in Treating Complex Denovo Femoropopliteal Arterial Disease: JET-RANGER
Table 21: Ranger Drug-Coated Balloon-Prospective, Non-randomized, Multicenter Clinical Study of the Boston Scientific Paclitaxel-coated PTA Balloon Catheter (Ranger and Ranger SL (OTW) DCB) in China
Table 22: Ranger Drug-Coated Balloon-Prospective, Randomized, Multi-center Study for the Treatment of Subjects with Symptomatic Femoropopliteal Artery Disease with the Ranger Paclitaxel Coated PTA Balloon Catheter (Study Arm) Versus the IN.PACT Drug Eluting Balloon (Control Arm)
Table 23: Ranger Drug-Coated Balloon-RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER Paclitaxel Coated Balloon Versus Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Table 24: Concept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 25: MagicTouch PTA Balloon Catheter-Product Status
Table 26: MagicTouch PTA Balloon Catheter-Product Description
Table 27: Concept Medical Inc-Ongoing Clinical Trials Overview
Table 28: MagicTouch PTA Balloon Catheter-Clinical Use and Safety of the Xtreme Touch (Magic Touch PTA)-Neo Sirolimus Coated PTA Balloon Catheter in the Treatment of Infrainguinal Peripheral Arterial Disease: XTOSI Pilot Study
Table 29: MagicTouch PTA Balloon Catheter-Randomized Controlled Trial of First SirolimUs Coated Balloon Versus Standard Balloon Angioplasty in the Treatment of Below the Knee Arterial Disease: FUTURE BTK
Table 30: MagicTouch PTA Balloon Catheter-Randomized Controlled Trial of First Sirolimus Coated Balloon Versus Standard Balloon Angioplasty in the Treatment of Superficial Femoral Artery and Popliteal Artery Disease
Table 31: Contego Medical LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Tibial Artery Drug Eluting Balloon-Product Status
Table 33: Tibial Artery Drug Eluting Balloon-Product Description
Table 34: eucatech AG Pipeline Products & Ongoing Clinical Trials Overview
Table 35: Support-Product Status
Table 36: Support-Product Description
Table 37: Genesis MedTech International Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 38: Chocolate Touch-Product Status
Table 39: Chocolate Touch-Product Description
Table 40: Genesis MedTech International Pvt Ltd-Ongoing Clinical Trials Overview

List of Figures

Figure 1: PTA Peripheral DCB Catheters-Pipeline Products by Stage of Development
Figure 2: PTA Peripheral DCB Catheters-Pipeline Products by Territory
Figure 3: PTA Peripheral DCB Catheters-Pipeline Products by Regulatory Path
Figure 4: PTA Peripheral DCB Catheters-Pipeline Products by Estimated Approval Date
Figure 5: PTA Peripheral DCB Catheters-Ongoing Clinical Trials

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

AnGes Inc
AngioCure, Inc.
Boston Scientific Corp
Concept Medical Inc
Contego Medical LLC
eucatech AG
Genesis MedTech International Pvt Ltd
Lifetech Scientific (Shenzhen) Co Ltd
Lutonix Inc
M.A. Med Alliance SA
Medtronic Plc
Micell Technologies Inc
Orchestra BioMed Inc
QualiMed Innovative Medizinprodukte GmbH
SiL Vascular Ltd
Spectranetics Corp
SurModics Inc
Tailored Medical Devices Inc
TransMed7 LLC
Vascular Nanotransfer Technologies

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2431EUR$2,500USD£2,014GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€4862EUR$5,000USD£4,029GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€7293EUR$7,500USD£6,043GBP

Table of Contents

Companies Mentioned (Partial List)

Related Topics

Related Reports

PTA Peripheral DCB Catheters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update

PTA Oxidation Catalyst Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

Purified Terephthalic Acid (PTA) Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

Purified Terephthalic Acid Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028

2024 Purified Terephthalic Acid (PTA) Market Outlook Report: Industry Size, Market Shares Data, Insights, Growth Trends, Opportunities, Competition 2023 to 2031